Repligen makes board appointment
This article was originally published in Scrip
Repligen (US) has elected Dr Glenn Cooper to its board of directors. He was formerly chairman and chief executive officer of Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in March. Dr Cooper has also worked as president and CEO of Progenitor, executive vice-president and chief operating officer of Sphinx Pharmaceuticals, and held various clinical and regulatory positions at Lilly.